表紙
市場調查報告書

全球呼吸藥物市場:到2027年的前景

Global Respiratory Drugs Market Outlook 2027

出版商 Research Nester 商品編碼 940310
出版日期 內容資訊 英文 185 Pages
商品交期: 最快1-2個工作天內
價格
全球呼吸藥物市場:到2027年的前景 Global Respiratory Drugs Market Outlook 2027
出版日期: 2020年05月01日內容資訊: 英文 185 Pages
簡介

全球的呼吸藥物市場從2019年到2027年將會有6.0%的年複合成長率,預計到達255億美元。

該報告研究全球呼吸藥物市場,提供市場概述,按種類,製劑,疾病,給藥方式,給藥路徑,通路,地區劃分,並且提供企業簡介, 管道分析等資訊。

目次

第1章 報告概述

第2章 簡介

  • 市場結構
  • 市場定義
  • 市場區分
  • 市場快照
  • 疾病分析
    • 氣喘
    • 慢性阻塞性肺疾病
    • 囊狀纖維化
    • 肺動脈高壓
    • 過敏性鼻炎
    • 特發性肺纖維化
  • 市場動力
    • 推動成長因素
    • 阻礙成長因素
    • 趨勢
    • 機會

第3章 市場分析:種類

  • 簡介
  • 市場規模及預測
    • 氣喘藥及COPD治療藥物
    • 咳嗽及感冒的常備藥物
    • 肺動脈高壓治療藥物
    • 特發性肺纖維化治療藥物

第4章 市場分析:製劑

  • 簡介
  • 市場規模及預測
    • 乾燥粉末
    • 藥片,膠囊
    • 噴霧
    • 糖漿和解決方案

第5章 市場分析:疾病

  • 簡介
  • 市場規模及預測
    • 氣喘
    • 慢性阻塞性肺疾病
    • 囊狀纖維化
    • 肺動脈高壓
    • 過敏性鼻炎
    • 特發性肺纖維化
    • 其他

第6章 市場分析:給藥種類

  • 簡介
  • 市場規模與預測
    • 獨立藥物
    • 組合藥物

第7章 市場分析:給藥路徑

  • 簡介
  • 市場規模與預測
    • 吸入
    • 經由口腔
    • 注射

第8章 市場分析:通路

  • 簡介
  • 市場規模與預測
    • 線上
    • 線下

第9章 市場分析:各地區

  • 簡介
  • 市場規模與預測
    • 北美
    • 拉丁美洲
    • 歐洲
    • 亞太地區
    • 中東/非洲

第10章 北美市場的分析及預測

  • 簡介
    • 國家
    • 種類
    • 製劑
    • 疾病
    • 給藥種類
    • 給藥路徑
    • 通路

第11章 拉丁美洲市場的分析及預測

  • 簡介
    • 國家
    • 種類
    • 製劑
    • 疾病
    • 給藥種類
    • 給藥路徑
    • 通路

第12章 歐洲市場的分析及預測

  • 簡介
    • 國家
    • 種類
    • 製劑
    • 疾病
    • 給藥種類
    • 給藥路徑
    • 通路

第13章 亞太市場的分析及預測

  • 簡介
    • 國家
    • 種類
    • 製劑
    • 疾病
    • 給藥種類
    • 給藥路徑
    • 通路

第14章 中東/非洲市場的分析及預測

  • 簡介
    • 國家
    • 種類
    • 製劑
    • 疾病
    • 給藥種類
    • 給藥路徑
    • 通路

第15章 企業簡介

  • ASTRAZENECA PLC
    • 概述
    • 產品類型/服務提供
    • 主要趨勢
    • SWOT分析
  • FIBROGEN,INC
    • 概述
    • 產品類型/服務提供
    • SWOT分析
  • NOVARTIS INTERNATIONAL AG
    • 概述
    • 產品類型/服務提供
    • 主要趨勢
    • SWOT分析
  • ABBOTT LABORATORIES
    • 概述
    • 產品類型/服務提供
    • SWOT分析
  • GLAXOSMITHKLINE PLC
    • 概述
    • 產品類型/服務提供
    • SWOT分析
  • F. HOFFMANN-LA ROCHE AG
    • 概述
    • 產品類型/服務提供
    • 主要趨勢
    • SWOT分析
  • MERCK&CO.,INC
    • 概述
    • 產品類型/服務提供
    • 策略
    • 主要趨勢
    • SWOT分析
  • SUNOVION PHARMACEUTICALS INC
    • 概述
    • 產品類型/服務提供
    • SWOT分析

第16章 管道分析

  • 氣喘藥以及COPD藥
    • 長效乙二型交感神經刺激劑(LABA)
    • 長效抗膽鹼藥物(LAMA)
    • 皮質類固醇
    • 白三烯
    • 黃嘌呤藥
  • 咳嗽及感冒的常備藥
    • 鎮痛劑
  • 抗組織胺藥物
  • 鼻塞藥
  • 祛痰劑
  • 肺動脈高壓
    • 內皮素受體阻斷劑
    • 抗凝血劑
  • 利尿劑
    • 可溶性鳥甘酸環化□(SGC)促進劑
  • 特發性肺纖維化治療藥物
    • □非尼酮
    • NINTEDANIB(尼達尼布)

第17章 縮寫

目錄

COVID-19 update included

The content of this report will be updated with the latest scenarios based on the global COVID-19 Pandemic

Respiratory disorders mainly consist of ailments affecting the lungs such as asthma, chronic obstructive pulmonary disease (COPD), acute respiratory infections, chronic bronchitis and several others.. These respiratory illnesses can be caused by a number of factors, some of them consisting of genetics, environment, and occupation as well as ageing. The market for respiratory drugs is anticipated to grow at a CAGR of 6.0% over the forecast period, i.e., 2019-2027. Further, the market is predicted to attain a significant market value of about USD 25,500 million by the end of 2027. Innovations in the healthcare industry are resulting in increasing research and development in the area of respiratory drugs. On the back of these factors, the market for respiratory drugs is anticipated to observe a significantly high growth in the next few years.

The market for respiratory drugs is segmented by drug, by formulation, by disease, by administration, by drug delivery, by distribution channel and by region. On the basis of disease, the market is segmented into asthma, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary hypertension, allergic rhinitis, idiopathic pulmonary fibrosis and others. The segment for asthma is predicted to attain the largest market value of about USD 8,500 million by the end of 2027 and grow at the highest CAGR over the forecast period. A report by the Centers for Disease Control and Prevention (CDC) stated that 1 among every 13 people is estimated to suffer from asthma and adult women are more prone to this condition as compared to adult men. This can explain the growth of this segment in the coming years.

On the basis of region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The largest market share was held by the market in North America, with a share of 40% in 2019. The market in this region is further estimated to continue holding the largest share over the forecast period. Moreover, this is closely followed by the market in Asia Pacific on the back of the rising developments and increasing innovations in the healthcare industry in the Asia Pacific region which account for the development of a higher number of respiratory drugs as compared with other regions.

Some of the key industry leaders in the global respiratory drugs market are: AstraZeneca, Fibrogen Inc., Novartis International AG, Abbott Laboratories, GlaxoSmithKline plc, F. Hoffmann-la Roche AG, Merck & Co. Inc. and Sunovion Pharmaceuticals Inc.

TABLE OF CONTENTS

1. Report Overview

  • 1.1. Global Respiratory Drugs Market Overview
  • 1.2. Why You Should Read This Report
  • 1.3. How This Report Delivers
  • 1.4. Key Questions Answered by This Analytical Report
  • 1.5. Who is This Report For?
  • 1.6. Methodology
    • 1.6.1. Primary Research
    • 1.6.2. Secondary Research
    • 1.6.3. Market Evaluation & Forecasting Methodology

2. Introduction to the Respiratory Drugs Market

  • 2.1. Respiratory Drugs Market Structure
  • 2.2. Respiratory Drugs Market Definition
  • 2.3. Global Respiratory Drugs Market Taxonomy
  • 2.4. Global Respiratory Drugs Market Snapshot
  • 2.5. Epidemiology Analysis

ASTHMA

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

CYSTIC FIBROSIS

PULMONARY HYPERTENSION

ALLERGIC RHINITIS

IDIOPATHIC PULMONARY FIBROSIS

  • 2.6. Global Respiratory Drugs Market Dynamics
    • 2.6.1. Global Respiratory Drugs Market: Driver
    • 2.6.2. Global Respiratory Drugs Market: Restraints
    • 2.6.1. Global Respiratory Drugs Market: Trends
    • 2.6.1. Global Respiratory Drugs Market: Opportunities

3. Global Respiratory Drugs Market, By Drug Type, 2019-2027

  • 3.1. Introduction
  • 3.2. Global Respiratory Drugs Market Size and Forecast, By Drug Type
    • 3.2.1. Anti-Asthmatics & COPD Drug Segment
    • 3.2.2. Cough & Cold Preparations Drug Segment
    • 3.2.3. Pulmonary Hypertension Segment
    • 3.2.4. Idiopathic Pulmonary Fibrosis Segment

4. Global Respiratory Drugs Market, By Formulation, 2019-2027

  • 4.1. Introduction
  • 4.2. Global Respiratory Drugs Market Size and Forecast, By Formulation
    • 4.2.1. Dry Powder Segment
    • 4.2.2. Tablets & Capsules Segment
    • 4.2.3. Sprays Segment
    • 4.2.4. Syrups & Solutions Segment

5. Global Respiratory Drugs Market, By Disease, 2019-2027

  • 5.1. Introduction
  • 5.2. Global Respiratory Drugs Market Size and Forecast, By Disease
    • 5.2.1. Asthma Segment
    • 5.2.2. Chronic Obstructive Pulmonary Disease Segment
    • 5.2.3. Cystic Fibrosis Segment
    • 5.2.4. Pulmonary Hypertension Segment
    • 5.2.5. Allergic Rhinitis Segment
    • 5.2.6. Idiopathic Pulmonary Fibrosis Segment
    • 5.2.7. Others Segment

6. Global Respiratory Drugs Market, By Administration, 2019-2027

  • 6.1. Introduction
  • 6.2. Global Respiratory Drugs Market Size and Forecast, By Administration
    • 6.2.1. Stand Alone Drugs Segment
    • 6.2.2. Combination Drugs Segment

7. Global Respiratory Drugs Market, By Drug Delivery, 2019-2027

  • 7.1. Introduction
  • 7.2. Global Respiratory Drugs Market Size and Forecast, By Drug Delivery
    • 7.2.1. Inhalational Segment
    • 7.2.2. Oral Segment
    • 7.2.3. Injection Segment

8. Global Respiratory Drugs Market, By Distribution Channel, 2019-2027

  • 8.1. Introduction
  • 8.2. Global Respiratory Drugs Market Size and Forecast, By Distribution Channel
    • 8.2.1. Online Segment
    • 8.2.2. Offline Segment

9. Global Respiratory Drugs Market, By Region, 2019-2027

  • 9.1. Introduction
  • 9.2. Global Respiratory Drugs Market Size and Forecast, By Region
    • 9.2.1. North America
    • 9.2.2. Latin America
    • 9.2.3. Europe
    • 9.2.4. Asia Pacific
    • 9.2.5. Middle East and Africa

10. North America Respiratory Drugs Market Analysis and Forecast, 2019-2027

  • 10.1. Introduction
    • 10.1.1. North America
  • 10.2. North America Respiratory Drugs Market Forecast, By Country, 2019-2027
  • 10.3. North America Respiratory Drugs Market Forecast, By Drug Type, 2019-2027
  • 10.4. North America Respiratory Drugs Market Forecast, By Formulation, 2019-2027
  • 10.5. North America Respiratory Drugs Market Forecast, By Disease, 2019-2027
  • 10.6. North America Respiratory Drugs Market Forecast, By Administration, 2019-2027
  • 10.7. North America Respiratory Drugs Market Forecast, By Drug Delivery, 2019-2027
  • 10.8. North America Respiratory Drugs Market Forecast, By Distribution Channel, 2019-2027

11. Latin America Respiratory Drugs Market Analysis and Forecast, 2019-2027

  • 11.1. Introduction
    • 11.1.1. Latin America
  • 11.2. Latin America Respiratory Drugs Market Forecast, By Country, 2019-2027
  • 11.3. Latin America Respiratory Drugs Market Forecast, By Drug Type, 2019-2027
  • 11.4. Latin America Respiratory Drugs Market Forecast, By Formulation, 2019-2027
  • 11.5. Latin America Respiratory Drugs Market Forecast, By Disease, 2019-2027
  • 11.6. Latin America Respiratory Drugs Market Forecast, By Administration, 2019-2027
  • 11.7. Latin America Respiratory Drugs Market Forecast, By Drug Delivery, 2019-2027
  • 11.8. Latin America Respiratory Drugs Market Forecast, By Distribution Channel, 2019-2027

12. Europe Respiratory Drugs Market Analysis and Forecast, 2019-2027

  • 12.1. Introduction
    • 12.1.1. Europe
  • 12.2. Europe Respiratory Drugs Market Forecast, By Country, 2019-2027
  • 12.3. Europe Respiratory Drugs Market Forecast, By Drug Type, 2019-2027
  • 12.4. Europe Respiratory Drugs Market Forecast, By Formulation, 2019-2027
  • 12.5. Europe Respiratory Drugs Market Forecast, By Disease, 2019-2027
  • 12.6. Europe Respiratory Drugs Market Forecast, By Administration, 2019-2027
  • 12.7. Europe Respiratory Drugs Market Forecast, By Drug Delivery, 2019-2027
  • 12.8. Europe Respiratory Drugs Market Forecast, By Distribution Channel, 2019-2027

13. Asia Pacific Respiratory Drugs Market Analysis and Forecast, 2019-2027

  • 13.1. Introduction
    • 13.1.1. Asia Pacific
  • 13.2. Asia Pacific Respiratory Drugs Market Forecast, By Country, 2019-2027
  • 13.3. Asia Pacific Respiratory Drugs Market Forecast, By Drug Type, 2019-2027
  • 13.4. Asia Pacific Respiratory Drugs Market Forecast, By Formulation, 2019-2027
  • 13.5. Asia Pacific Respiratory Drugs Market Forecast, By Disease, 2019-2027
  • 13.6. Asia Pacific Respiratory Drugs Market Forecast, By Administration, 2019-2027
  • 13.7. Asia Pacific Respiratory Drugs Market Forecast, By Drug Delivery, 2019-2027
  • 13.8. Asia Pacific Respiratory Drugs Market Forecast, By Distribution Channel, 2019-2027

14. Middle East & Africa Respiratory Drugs Market Analysis and Forecast, 2019-2027

  • 14.1. Introduction
    • 14.1.1. MEA
  • 14.2. MEA Respiratory Drugs Market Forecast, By Country, 2019-2027
  • 14.3. MEA Respiratory Drugs Market Forecast, By Drug Type, 2019-2027
  • 14.4. MEA Respiratory Drugs Market Forecast, By Formulation, 2019-2027
  • 14.5. MEA Respiratory Drugs Market Forecast, By Disease, 2019-2027
  • 14.6. MEA Respiratory Drugs Market Forecast, By Administration, 2019-2027
  • 14.7. MEA Respiratory Drugs Market Forecast, By Drug Delivery, 2019-2027
  • 14.8. MEA Respiratory Drugs Market Forecast, By Distribution Channel, 2019-2027

15. Company Profile

  • 15.1. ASTRAZENECA PLC
    • 15.1.1. Overview
    • 15.1.2. Product Type/Service Offerings
    • 15.1.3. Key Developments
    • 15.1.4. SWOT ANALYSIS
  • 15.2. FIBROGEN, INC
    • 15.2.1. Overview
    • 15.2.2. Product Type/Service Offerings
    • 15.2.3. SWOT Analysis
  • 15.3. NOVARTIS INTERNATIONAL AG
    • 15.3.1. Overview
    • 15.3.2. Product Type/Service Offerings
    • 15.3.3. Key Developments
    • 15.3.4. SWOT ANALYSIS
  • 15.4. ABBOTT LABORATORIES
    • 15.4.1. Overview
    • 15.4.2. Product Type/Service Offerings
    • 15.4.3. SWOT Analysis
  • 15.5. GLAXOSMITHKLINE PLC
    • 15.5.1. Overview
    • 15.5.2. Product Type/Service Offerings
    • 15.5.3. SWOT Analysis
  • 15.6. F. HOFFMANN-LA ROCHE AG
    • 15.6.1. Overview
    • 15.6.2. Product Type/Service Offerings
    • 15.6.3. Key Developments
    • 15.6.4. SWOT Analysis
  • 15.7. MERCK & CO., INC
    • 15.7.1. Overview
    • 15.7.2. Product Type/Service Offerings
    • 15.7.3. Strategy (s)
    • 15.7.4. Key Developments
    • 15.7.5. SWOT Analysis
  • 15.8. SUNOVION PHARMACEUTICALS INC
    • 15.8.1. Overview
    • 15.8.2. Product Type/Service Offerings
    • 15.8.3. SWOT Analysis

16. Respiratory Drugs Pipeline Analysis

  • 16.1. ANTI-ASTHMATICS AND COPD DRUG
    • 16.1.1. LONG-ACTING BETA-AGONISTS (LABA)

Study Description

Study Design

    • 16.1.2. LONG-ACTING MUSCARINIC ANTAGONISTS (LAMA)

Study Description

Study Design

Study Description

Study Design

    • 16.1.3. CORTICOSTEROIDS

Study Description

Study Design

Study Description

Study Design

Study Description

Study Design

    • 16.1.4. LEUKOTRIENE

Study Description

Study Design

Study Description

Study Design

    • 16.1.5. XANTHINES

Study Description

Study Design

  • 16.2. COUGH AND COLD PREPARATIONS DRUG
    • 16.2.1. ANTITUSSIVES

Study Description

Study Design

Study Description

Study Design

  • 16.3. ANTIHISTAMINES

Study Description

Study Design

Study Description

Study Design

  • 16.4. DECONGESTANTS

Study Description

Study Design

Study Description

Study Design

  • 16.5. EXPECTORANTS

Study Description

Study Design

Study Description

Study Design

  • 16.6. PULMONARY HYPERTENSION
    • 16.6.1. ENDOTHELIN RECEPTOR ANTAGONISTS

Study Description

Study Design

    • 16.6.2. ANTICOAGULANTS

Study Description

Study Design

Study Description

Study Design

  • 16.7. DIURETICS

Study Description

Study Design

Study Description

Study Design

    • 16.7.1. SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATOR

Study Description

Study Design

Study Description

Study Design

  • 16.8. IDIOPATHIC PULMONARY FIBROSIS
    • 16.8.1. PIRFENIDONE

Study Description

Study Design

Study Description

Study Design

    • 16.8.2. NINTEDANIB

Study Description

Study Design

Study Description

Study Design

17. Acronyms